TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18447214
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group treated with oral administration of Weilexin
Study: 1596703
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alpha-interferon (5 x 10(5) iu, twice a week)
Study: 6426073
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 20 mg inhaled from a pressurised metered dose inhaler
Study: 29150312
Drug: Childcare intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Childcare intervention with parental component (CC+HOME)
Study: 28127507
Drug: Dalfampridine treatment
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine treatment for 12–14 days
Study: 23449533
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of de novo antibodies
Study: 10759625
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg q.d.s.
Study: 30054173
Drug: Self-led VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-led VR exposure therapy followed by the same transition program (after waiting-list)
Study: 11348533
Drug: melarsoprol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: melarsoprol treatment
Study: 28240760
Drug: Focal muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal muscle vibration therapy combined with progressive modular rebalancing
Study: 28774880
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 intravenously/subcutaneously daily for 3 consecutive days on a 28-day cycle
Study: 26082889
Drug: Facial affect
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facial affect discrimination training (20 daily 1-hour sessions over 4 weeks)
Study: 8747670
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (0.02% quinine-hydrochloride)
Study: 18442722
Drug: RATG induction
Normalized name: rATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RATG induction therapy
Study: 1317643
Drug: 3-mg PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-mg PGE2 vaginal tablet
Study: 22653382
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly for 24 weeks (etanercept/etanercept group)
Study: 25154195
Drug: High-tone power
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-tone power therapy for 60 minutes for 15 days
Study: 10518847
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS)
Study: 3524441
Drug: Intranasal rIFN-alpha
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal rIFN-alpha A (1.5 X 10(6) IU)
Study: 1659438
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose naloxone
Study: 11465625
Drug: Total immunoglobulin
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total immunoglobulin M and total immunoglobulin G concentrations
Study: 30884986
Drug: Pertuzumab with
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab with trastuzumab and chemotherapy (THP)
Study: 20977130
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral meclizine (experimental group)
Study: 26694939
Drug: Aprepitant 80 mg
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 80 mg orally with ondansetron 4 mg intravenously
Study: 21984038
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg)
Study: 14607208
Drug: Metoprolol, 50
Normalized name: Hydrochlorothiazide-Metoprolol, 50 mg-100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 50 mg t.i.d. for 6 months
Study: 12144575
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, all b.d.)
Study: 12144575
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole 20 mg b.d., tetracycline chloride 500 mg, metronidazole 500 mg, bismuth subcitrate 120 mg, all t.d.s.)
Study: 11684628
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C treatment
Study: 22794217
Drug: 1 mg/mL
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL berberine plus 1% CHX
Study: 21755540
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 mg BID
Study: 12424330
Drug: Tomato sauce
Normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES TOMATO SAUCE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato sauce supplementation (30 mg of lycopene/day) for 3 weeks
Study: 26813209
Drug: Daily 4000
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily 4000 IU vitamin D plus a prenatal vitamin containing 400 IU vitamin D
Study: 12184147
Drug: Mix Group
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix Group (MG) - 50% olein
Study: 15693870
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin 200 U/kg twice a week, subcutaneously for 6 weeks
Study: 15693870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (150 premature infants receiving conventional supportive therapy)
Study: 12390617
Drug: Buccal prochlorperazine
Normalized name: prochlorperazine Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal prochlorperazine (PCZ) 3 mg
Study: 17196475
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and ranitidine
Study: 1519781
Drug: Epidural normal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural normal saline (20 ml) before surgical incision, followed by epidural fentanyl (4 micrograms/kg, in 20 ml normal saline) infused 15 min after incision.
Study: 10331327
Drug: Prednisone oral
Normalized name: prednisone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone oral solution
Study: 30394326
Drug: Dopaminergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic therapy
Study: 10886272
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (10‐20 mg three times a week for 2 months)
Study: 28295959
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/d
Study: 26367217
Drug: melphalan 280
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan 280 mg/m² (mel280)
Study: 30577901
Drug: Recovery Line
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery Line (RL) + Treatment-as-Usual (TAU)
Study: 22801094
Drug: AS03-adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted vaccines
Study: 18199893
Drug: Piperaquine phosphate
Normalized name: Piperaquine phosphate
DrugBank: Piperaquine (DB13941)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Piperaquine phosphate 1250 mg
Study: 14648339
Drug: Low-dose enalapril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose enalapril (0.2 mg/kg daily)
Study: 14648339
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of 20 weeks treatment
Study: 2210807
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol beer (reduced from 537 to 57 ml/week)
Study: 2210807
Drug: Normal alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal alcohol intake (543 to 557 ml/week)
Study: 29180278
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg
Study: 31828841
Drug: Slow rehydration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow rehydration (intravenous fluid over 12 hours)
Study: 2658898
Drug: Intravenous porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous porcine intestinal mucosal heparin
Study: 26430929
Drug: Synbiotic bread
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic bread containing Lactobacillus sporogenes (1 × 10^8 CFU) and 0.07 g inulin per 1 g
Study: 21530322
Drug: Reverse total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reverse total shoulder arthroplasty with varying humeral versions (0°, 10°, 20° retroversion) and implant thicknesses (‐3, 0, +3 mm from baseline)
Study: 19099009
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg
Study: 6436890
Drug: Combined doses
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined doses of scopolamine 1.2 mg and nicotine 1.5 mg
Study: 19673958
Drug: Tissue-engineered bone
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-engineered bone (test site - Oral Bone, BioTissue, Freiburg, Germany)
Study: 20177294
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy
Study: 9049578
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg once daily for 7 days
Study: 15606444
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 12.5 mg and 25 mg oral doses
Study: 7386801
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate administration in large amounts
Study: 27231940
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injection (Control)
Study: 15111679
Drug: Pergolide 0.25
Normalized name: pergolide 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide 0.25 to 0.75 mg in the evening for 6 weeks
Study: 11868930
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 microg and salmeterol 50 microg combination product (FSC) twice daily
Study: 1320887
Drug: Cyclosporin (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (CsA) at a dose of 7.5-10 mg/day for the first 6 months, then not exceeding 5 mg/kg/day thereafter
Study: 18596271
Drug: Epinephrine alone
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine alone (1 mg)
Study: 12012079
Drug: Bicarbonate supplement
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate supplement (0.3 g x kg(‐1) of body mass)
Study: 23018219
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate (UPA) 5 or 10 mg daily for 13 weeks
Study: 1582303
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g every 8 h
Study: 8150763
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g every 12 h
Study: 2581324
Drug: Isoxicam 200
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoxicam 200 mg once daily
Study: 16292592
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg nocturnally administered for 15 days
Study: 8405014
Drug: 0.150 mg
Normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.150 mg desogestrel + 2.0 mg micronized 17 beta‐oestradiol
Study: 21876066
Drug: Adjunctive levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjunctive levetiracetam
Study: 18314112
Drug: Early CC
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early CC group
Study: 9840608
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine (group 1)
Study: 7863249
Drug: Nizatidine 10
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine 10 mg/h
Study: 25487082
Drug: Elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elosulfase alfa 2.0 mg/kg administered weekly
Study: 27300645
Drug: ONO-9054 30
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-9054 30 μg/mL
Study: 15838525
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of DHA and 0.75 g of EPA daily for 6 months
Study: 23150927
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 mcg)
Study: 15163329
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg PTU
Study: 10369190
Drug: Prednisone or
Normalized name: prednisone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone or prednisolone at 60 mg/m2 per day (up to 80 mg/day) for four to six weeks, followed by 40 mg/m2 every other day for another four to six weeks
Study: 10369190
Drug: Prednisone at
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone at 60 mg/m2/day (up to 80 mg/day) until urine is protein free for three days, then 40 mg/m2 every other day for another month
Study: 7996346
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered immune globulin, 0.5 gm/kg per day for 5 consecutive days (n = 19)
Study: 28318138
Drug: 6-month dual
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month dual antiplatelet therapy (DAPT)
Study: 8635703
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy (adrenaline and polidocanol)
Study: 18946626
Drug: Neridronate 25
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 25 mg IM every 2 weeks
Study: 18946626
Drug: Neridronate 25
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 25 mg IM every 4 weeks
Study: 30088663
Drug: ACT-246475 32
Normalized name: ACT-246475
DrugBank: Selatogrel (DB15163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-246475 32 mg
Study: 30989330
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg once daily
Study: 16270637
Drug: Ximelagatran 24
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 24 mg twice daily
Study: 8201222
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (alone)
Study: 9577904
Drug: Erythromycin 50
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 50 mg i.v.
Study: 9577904
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg i.v.
Study: 345489
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of LH-RH
Study: 26853211
Drug: Indigenous Oral
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigenous Oral Health Literacy Project (IOHLP) participants
Study: 29570467
Drug: Bedside respiratory
Normalized name: Bedside-Care
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bedside respiratory muscle training (twice a day for 3 weeks) including breath stacking exercise, inspiratory muscle training, and expiratory muscle training.
Study: 12222753
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of metformin with placebo
Study: 12416945
Drug: Cardioselective β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioselective β-blocker (single dose)
Study: 16088265
Drug: Mind-body therapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body therapy
Study: 12017349
Drug: Verteporfin 3
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin 3 to 20 mg/m2 of body surface area infused over 1.5 to 45 minutes
Study: 134722
Drug: Ipratropiumbromide by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropiumbromide by i.v. injection (max dose 0.28 mg)
Study: 15298643
Drug: Micafungin 75
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micafungin 75 mg
Study: 17448371
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4 to 8 mg daily (n = 110)
Study: 30817466
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment of SBP to less than 120 mmHg (SPRINT)
Study: 30817466
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment of SBP to less than 120 mmHg (THIN)
Study: 15238279
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg copper/L
Study: 25048824
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (IDet)
Study: 8969280
Drug: Diet P
Normalized name: T-Diet Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet P (32 g protein/d)
Study: 8969280
Drug: Diet M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet M (10 mmol L-methionine/d)
Study: 24521771
Drug: tacrolimus extended-release
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tacrolimus extended-release (Astagraf XL)
Study: 15842142
Drug: Prednisone 30
Normalized name: prednisone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 30 mg, once a day
Study: 30295335
Drug: Crizanlizumab 5
Normalized name: Crizanlizumab
DrugBank: Crizanlizumab (DB15271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crizanlizumab 5 mg/kg
Study: 25131223
Drug: Biologics-treated groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics-treated groups (RhCTLA4-Ig and infliximab combined)
Study: 21148531
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (TIV)
Study: 10536064
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of budesonide (200-400 microg/day)
Study: 2150533
Drug: Untreated hypertensives
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated hypertensives with randomly allocated treatment
Study: 9126802
Drug: Silymarin 600
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 600 mg per day
Study: 19552488
Drug: Blonanserin 10
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin 10 mg
Study: 21552707
Drug: Enzymatic solution
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatic solution
Study: 19856793
Drug: Isoxsuprine hydrochloride
Normalized name: Isoxsuprine Hydrochloride
DrugBank: Isoxsuprine (DB08941)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoxsuprine hydrochloride 30 mg
Study: 19856793
Drug: Isoxsuprine hydrochloride
Normalized name: Isoxsuprine Hydrochloride
DrugBank: Isoxsuprine (DB08941)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoxsuprine hydrochloride 60 mg